October 17, 2023
Tools/Drug Development Support Tech
Company Description: GATC Health is an AI company transforming drug development and disease prediction. Our proprietary Multiomics Advanced Technology™ (MAT) simulates complex human physiology for therapeutic target (disease) identification, accurate drug discovery, and detailed insight into safety and efficacy. The company is developing its own compounds, collaborating with innovators and R&D departments to optimize and speed up their development, as well as helping investors in their due diligence by better predicting clinical trial outcomes. GATC’s talented team includes veterans from IBM Watson, Roche, MIT, Northrop Grumman, and the Human Genome Project. A renowned and active board of advisors, including Herb Boyer, co-founder of Genentech, Tomas Philipson, former Acting Chairman of the Council of Economic Advisors in the White House and senior economic advisor to the heads of the FDA and CMS, and Dr Richard Schatz, co-inventor of the coronary stent, among others.
CEO/Top Company Official
Lead Product in Development
GATC owns and operates an AI platform for due diligence for M&A departments and financial institutions funding drug development, for drug makers in assessing returns investing in the next trial phase or VC or PE firms assessing portfolio risks. GATC's AI platform has proven ability to identify the beneficial effect of a drug candidate in a human with 88% accuracy, while identifying which drugs will fail—and why—with 84% accuracy. The current industry average is less than 10% success rate for drugs entering clinical trials.
Development Phase of Primary Product
Number Of Unlicensed Products
In less than 18 months, GATC discovered novel compounds resulting in five novel drug candidates to address Opioid Use Disorder, Cocaine Addiction, PTSD, and other major neurological disorders. UC Irvine has completed animal trials for GATC’s first drug candidate to treat opioid use disorder, with results to be made public in early Q4 of this year. Unlike existing OUD abatement medications, GATC’s drug candidate is not an opioid, so it is not habit forming and with no potential for diversion, thus removing its “street value”. The compound promotes remodeling of the brain’s limbic system by re-wiring learned addiction patterns and maintains sufficient dopamine levels to increase comfort, and thus support continued addiction recovery. In addition to the five compounds that havre completed in-silico design & testing, GATC has compounds for eight additional diseases in our pipeline.